Coronavirus Drug
-
{
- All
- News
- Videos
-
Sun Pharma To Make Eli Lilly's Covid Medicine In India; Shares Gain
Sun Pharmaceutical shares rose as much as 3.51% to hit an intraday high of Rs 703.40 after it signed an agreement with Eli Lilly to make baricitinib.
-
Scientists Identify Drug Targets For Pan-Coronavirus Treatment
Scientists have identified the most highly conserved drug-binding pockets in viral proteins from COVID-19 patient samples and from other coronaviruses, revealing the most promising targets for pan-coronavirus drugs.
-
Foreign Vaccines Like Pfizer, Moderna A Step Closer With Key India Waiver
In a big move to clear the way for foreign vaccines like Pfizer and Moderna, the drug regulator has done away with the requirement of India-specific trials.
-
Sun Pharma To Make Eli Lilly's Covid Medicine In India; Shares Gain
Sun Pharmaceutical shares rose as much as 3.51% to hit an intraday high of Rs 703.40 after it signed an agreement with Eli Lilly to make baricitinib.
-
Lupin Launches Covid-19 Drug Favipiravir In India At Rs 49 Per Tablet
Lupin to launch Favipiravir drug in India under the brand name ‘Covihalt’ for the treatment of mild to moderate Covid-19 symptoms.
-
Sun Pharma Company Launches COVID-19 Drug Favipiravir In India
Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
-
Ramdev's COVID Drug Row Ends, To Be Sold For Immunity, Not As Cure
Patanjali Ayurved's Swasari Coronil kit, controversially launched as a coronavirus cure and being investigated by government medical experts, will be available across the country, Yoga teacher Ramdev said today, claiming there was no restriction on selling the kit for COVID-19 "management".
-
WHO Urges Rapid Production Of COVID-19 Drug Dexamethasone For Patients
The World Health Organization called Monday for a rapid increase in production of the steroid dexamethasone, after British clinical trials found it had life-saving potential for critically-ill coronavirus patients.
-
US Pharma Firm Gilead To Make 2 Million Courses Of Remdesivir By 2020 End
Gilead Sciences Inc is planning to make more than two million courses of its potential COVID-19 drug remdesivir by the end of the year and start trials of an easier-to-use inhaled version in August, the company said on Monday.
-
WHO Sees "Green Shoots Of Hope" In Fight Against COVID-19 Pandemic
Signs of hope are starting to show in the fight against the COVID-19 pandemic, the World Health Organization (WHO) said on Wednesday, but it added that countries must continue to work on prevention measures to limit the spread of the new coronavirus.
-
Gilead's Drug Prevents Lung Damage In COVID-19 Study On Monkeys: Report
Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaque monkeys infected with the new coronavirus, a study published in medical journal Nature showed on Tuesday.
-
Health Ministry Drafts Rules To Help Coronavirus Patients Access New Drugs
Seeking to facilitate the availability of experimental drugs for severely-ill COVID-19 patients, the Union Health Ministry has issued a draft notification for "compassionate use" of any unapproved drug that is in the phase-III clinical trial globally.
-
Anti-Malaria Drug Hydroxychloroquine's Coronavirus Trials To Resume: WHO
The World Health Organization announced Wednesday that clinical trials of the drug hydroxychloroquine will resume as it searches for potential coronavirus treatments.
-
Gilead Trades That Made Millions On COVID-19 Drug News Under Scrutiny
Well-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.
-
Panel Formed To Suggest Reforms In Drug Regulatory System
A high-level committee of experts has been formed by the government to recommend reforms in India's drug regulatory system so that approval processes can be fast-tracked.
-
Sun Pharma To Make Eli Lilly's Covid Medicine In India; Shares Gain
Sun Pharmaceutical shares rose as much as 3.51% to hit an intraday high of Rs 703.40 after it signed an agreement with Eli Lilly to make baricitinib.
-
Scientists Identify Drug Targets For Pan-Coronavirus Treatment
Scientists have identified the most highly conserved drug-binding pockets in viral proteins from COVID-19 patient samples and from other coronaviruses, revealing the most promising targets for pan-coronavirus drugs.
-
Foreign Vaccines Like Pfizer, Moderna A Step Closer With Key India Waiver
In a big move to clear the way for foreign vaccines like Pfizer and Moderna, the drug regulator has done away with the requirement of India-specific trials.
-
Sun Pharma To Make Eli Lilly's Covid Medicine In India; Shares Gain
Sun Pharmaceutical shares rose as much as 3.51% to hit an intraday high of Rs 703.40 after it signed an agreement with Eli Lilly to make baricitinib.
-
Lupin Launches Covid-19 Drug Favipiravir In India At Rs 49 Per Tablet
Lupin to launch Favipiravir drug in India under the brand name ‘Covihalt’ for the treatment of mild to moderate Covid-19 symptoms.
-
Sun Pharma Company Launches COVID-19 Drug Favipiravir In India
Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
-
Ramdev's COVID Drug Row Ends, To Be Sold For Immunity, Not As Cure
Patanjali Ayurved's Swasari Coronil kit, controversially launched as a coronavirus cure and being investigated by government medical experts, will be available across the country, Yoga teacher Ramdev said today, claiming there was no restriction on selling the kit for COVID-19 "management".
-
WHO Urges Rapid Production Of COVID-19 Drug Dexamethasone For Patients
The World Health Organization called Monday for a rapid increase in production of the steroid dexamethasone, after British clinical trials found it had life-saving potential for critically-ill coronavirus patients.
-
US Pharma Firm Gilead To Make 2 Million Courses Of Remdesivir By 2020 End
Gilead Sciences Inc is planning to make more than two million courses of its potential COVID-19 drug remdesivir by the end of the year and start trials of an easier-to-use inhaled version in August, the company said on Monday.
-
WHO Sees "Green Shoots Of Hope" In Fight Against COVID-19 Pandemic
Signs of hope are starting to show in the fight against the COVID-19 pandemic, the World Health Organization (WHO) said on Wednesday, but it added that countries must continue to work on prevention measures to limit the spread of the new coronavirus.
-
Gilead's Drug Prevents Lung Damage In COVID-19 Study On Monkeys: Report
Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaque monkeys infected with the new coronavirus, a study published in medical journal Nature showed on Tuesday.
-
Health Ministry Drafts Rules To Help Coronavirus Patients Access New Drugs
Seeking to facilitate the availability of experimental drugs for severely-ill COVID-19 patients, the Union Health Ministry has issued a draft notification for "compassionate use" of any unapproved drug that is in the phase-III clinical trial globally.
-
Anti-Malaria Drug Hydroxychloroquine's Coronavirus Trials To Resume: WHO
The World Health Organization announced Wednesday that clinical trials of the drug hydroxychloroquine will resume as it searches for potential coronavirus treatments.
-
Gilead Trades That Made Millions On COVID-19 Drug News Under Scrutiny
Well-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.
-
Panel Formed To Suggest Reforms In Drug Regulatory System
A high-level committee of experts has been formed by the government to recommend reforms in India's drug regulatory system so that approval processes can be fast-tracked.
